Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vita Life Sciences Limited (VLS.AX)
Kirrawee, NSW, AU
Vita Life Sciences Limited is an Australian healthcare company specializing in the formulation, packaging, distribution, and sale of vitamins and nutritional supplements. The company's reach spans Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. In addition to core supplements, their product range encompasses minerals, various herbs, and superfoods. They offer solutions targeting a broad spectrum of therapeutic areas, including nervous system support, general nutrition, immunity, hair, skin, and nails, liver and digestion, weight management, cardiovascular health, pain and inflammation, pregnancy and breastfeeding, and health specifically for men, women, and children. Products also provide antioxidant benefits and support for bones and joints. Marketed under their prominent brands—Herbs of Gold, VitaHealth, and VitaScience—these offerings are sold through pharmacies and health food channels. Established in 1947, Vita Life Sciences Limited is headquartered in Kirrawee, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.25% | -6.25% | -5.14% | -10.11% | -0.41% | -6.98% | +26.98% | +54.84% | +98.35% | +72.66% | +126.42% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+17.3% ★ Q4'25: +20.9% (vs Q4'23)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+12.5% Q4'25: +7.7% (vs Q4'23)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+16.6% ★ Q4'25: +20.9% (vs Q4'23)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+15.7% ★ Q4'25: +16.1% (vs Q4'23)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+42.5% ★ Q4'25: +90.7% (vs Q4'23)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+3.4% Q4'25: +1.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.27× ★ Q4'25: 0.14× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
|---|---|---|---|---|---|
| Revenue |
35.41M
est: 36.44M (-2.8%)
|
36.58M
est: 38.44M (-4.8%)
|
38.58M
est: 37.37M (+3.2%)
|
37.86M
est: 37.32M (+1.4%)
|
37.74M
est: 42.18M (-10.5%)
|
| EBITDA |
5.65M
est: 6.65M (-15.1%)
|
7.18M
est: 6.87M (+4.4%)
|
6.37M
est: 6.84M (-6.8%)
|
6.06M
est: 6.12M (-1.0%)
|
5.15M
est: 7.69M (-33.1%)
|
| EBIT |
5.64M
est: 6.34M (-11.1%)
|
7.06M
est: 6.55M (+7.7%)
|
6.26M
est: 6.37M (-1.8%)
|
5.80M
est: 6.18M (-6.1%)
|
4.81M
est: 7.33M (-34.4%)
|
| Net Income |
4.75M
est: 4.39M (+8.2%)
|
7.28M
est: 5.53M (+31.7%)
|
4.39M
est: 3.52M (+24.9%)
|
3.34M
est: 4.45M (-24.9%)
|
2.86M
|
| SGA |
16.95M
est: 14.88M (+13.9%)
|
17.54M
est: 15.39M (+14.0%)
|
19.32M
est: 14.96M (+29.1%)
|
18.00M
est: 21.01M (-14.3%)
|
17.87M
est: 17.23M (+3.7%)
|
| EPS |
0.09
est: 0.08 (+6.9%)
|
0.13
est: 0.10 (+30.0%)
|
0.08
est: 0.06 (+24.0%)
|
0.06
est: 0.06 (+1.8%)
|
0.05
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-14 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-13 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-12 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-05 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-04 | A+ | 4/5 | 5/5 | 5/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 5/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Andrew W. O'Keefe | MD & Director | 595.6K | male |
| K. S. Beh | Chief Executive Officer of Vita Life Sciences Malaysia & Singapore | 555.9K | female |
| Shaun Rutherford | Chief Executive Officer of Herbs of Gold Australia | 382.4K | male |
| Chin Leng Khoo AGIA | Chief Financial Officer & Company Secretary | 253.6K | male |
| Melissa Pereira | Head of Marketing | 177.3K | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VLS.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
